All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the AML Hub spoke with Talati Chetasi, Moffitt Cancer Center, Tampa, US. We asked, How has the COVID-19 pandemic impacted patients with AML?
How has the COVID-19 pandemic impacted patients with AML?
Chetasi discusses how COVID-19 has impacted treatment options for AML, family visitation for patients receiving intensive chemotherapy, and the availability of donors for blood transfusions.
COVID-19 and EBMT recommendations for patients with hematological malignancies
The latest guidelines and recommendations for the management of Coronavirus Disease 2019 (COVID-19) in patients with hematological malignancies, including acute myeloid...
Positive topline results from a phase II trial of antroquinonol for patients with AML
On November 26, 2020, a press release on topline results from a phase II trial (NCT03823352) of antroquinonol in adult patients with acute myeloid leukemia (AML)...
Subscribe to get the best content related to AML delivered to your inbox